Upcoming Webinars

Uterine mesenchymal neoplasms: new and evolving entities

Wednesday, June 26, 2024
10:00 PM UTC 
See all time zones 

In this session, we will review new and evolving uterine mesenchymal entities as well as biomarker and molecular assays to aid in these diagnoses. Additionally, appropriate diagnostic terminology will be covered in the absence of accessible immunohistochemistry and molecular testing.

This webinar is complimentary for IGCS members. 

Brooke Howitt, MD 
Associate Professor of Pathology 
Stanford University School of Medicine 

Adrian Suarez, MD
Surgical Pathology Director   
The Ohio State University Wexner Medical Center 

Recently Recorded

Palliative Care in Disaster and Conflict Settings

Political and ethnic conflict, and geological and climatic disasters, result in suffering on a massive scale, particularly in low- and middle-income countries with fragile health care systems. Palliative care, defined most often as a response to physical, psychological, social, or spiritual suffering of those with “life-limiting illness,” is crucial for those with such illnesses in humanitarian settings. But those without life-limiting illnesses also suffer severely, due, for example, to gender-based violence or to witnessing and fleeing from extreme violence. This webinar will explore how, in humanitarian settings, palliative care can and should be true to its mission of responding to suffering without the constraint of focusing only on those with life-limiting illnesses.

This webinar is complimentary for IGCS members. 

Eric L. Krakauer, MD, PhD
Director, Program in Global Palliative Care
Associate Professor of Medicine
Associate Professor of Global Health & Social Medicine
Harvard Medical School

Annekathryn “AK” Goodman, MD, MS, MPH
Professor of Obstetrics, Gynecology and Reproductive Biology
Harvard Medical School

Nahla Gafer, MD
Clinical Oncologist & Head Palliative Care Unit
Khartoum Oncology Hospital
Director, Palliative Care Continuous Education
Comboni College of Science and Technology

 Peter Grant, MD
Assoc Professor, University of Melbourne
Gynaecological Oncologist, Western Health, Melbourne

 Anisa Mburu, MD
Gynecologic Oncologist
Aga Khan Hospital and International Cancer Institute

 An Evolving Frontier - Understanding Novel Treatment Options for
The Management of Advanced Stage or Recurrent Endometrial Cancers

Shannon N. Westin, M.D., M.P.H., F.A.C.O.G., USA
Linda Ryan, USA

In this IGCS Advances & Updates special presentation, Linda Ryan, a metastatic recurrent cervical cancer survivor and patient research advocate shares her story and experience with clinical trials. Linda is joined by her gynecologic oncologist, Dr. Shannon Westin, a professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Listen to Linda and Dr. Westin as they discuss recent approval and therapeutic options for patients with recurrent cervical cancer.

Emerging Data in platinum resistance advanced ovarian cancer

Lainie P. Martin, MD
Leader, Gynecology/Oncology Program
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Associate Professor of Obstetrics and Gynecology
University of Pennsylvania Perelman School of Medicine

David O’Malley, MD  
Ohio State University Comprehensive Cancer Center-James Cancer Hospital &  
Solove Research Institute Professor 
Director, Division of Gynecologic Oncology 
Co-Director, Gyn Oncology Phase I Program 

 Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type,
Advanced or Recurrent Endometrial Carcinoma: XPORT-042 - Trial in Progress

Robert Coleman, MD, FACOG, FACS
Chief Medical Officer
Vaniam Group

Floor Backes, MD
Director of Clincial Research and Fellowship Director for the Division of Gynecologic Oncology
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center

Available as a Podcast! 

Would you rather listen to this recording? Listen on Education360 Learning Portal or the streaming services below!

Immunotherapy and its impact on overall survival
in patients with recurrent endometrial cancer

Matthew A. Powell, MD
Professor, Div Gyn Oncology
Chair Uterine Corpus Committee
National Cancer Institute sponsored NRG Oncology
Washington University School of Medicine

R. Wendel Naumann, M.D.
Director of Gynecologic Oncology Research
Associate Medical Director of Clinical Trials
Levine Cancer Institute – Hall Gynecologic Oncology Center

Newly Opened Phase 3 Study for Low
Grade Serous Ovarian Cancer

Rachel Grisham, MD
Section Head Ovarian Cancer
Director, Gynecologic Medical Oncology
Memorial Sloan Kettering Cancer Center

Susana Banerjee, MBBS, MA, PhD, FRCP
Consultant Medical Oncologist
Research Lead Gynaecology Unit
The Royal Marsden
Professor in Women’s Cancers,
Institute of Cancer Research, London

Dr. Rachel Grisham and Dr. Susana Banerjee discussed details about a potential clinical trial for your patients. The RAMP 301 trial is evaluating the novel combination of avutometinib + defactinib versus investigator’s choice of therapy in patients with recurrent low grade serous ovarian cancer.

Radiation Treatment for Gynecologic Malignancies
and the Vital Role of Nursing

Kayla Kafka-Peterson, RN, BSN
Nursing Supervisor II Radiation Oncology
Brachytherapy Program Operations Oversight
University of California Los Angeles (UCLA)

Puja Venkat, MD
Assistant Clinical Professor, Radiation Oncology
Equity, Diversity and Inclusion Co-Chair
University of California Los Angeles (UCLA)

Radiation therapy plays a critical role in the treatment of many types of gynecologic cancer. This webinar will explain the rationale behind radiation treatment for gynecologic malignancies, different treatment modalities (including both external beam radiation therapy and brachytherapy), as well as how to care for patients undergoing radiation therapy. Nursing care will be covered in-depth, with a special emphasis on patient education and side effect management. This webinar will focus heavily on external beam radiation therapy. We will have a second part to this webinar that will cover brachytherapy in depth.

Refresher on Selecting Genetic Testing
for Ovarian Cancer Treatment Decisions

Thomas C. Krivak, MD
Director, Division of Gynecologic Oncology 
Director, Gynecologic Oncology Research Program
The Western Pennsylvania Hospital

Leigha Senter-Jamieson, MS, CGC
Certified Genetic Counselor
Associate Director of Division of Human Genetics
The Ohio State University

Supported in part by GSK

The Evolving Treatment Landscape for The Management of Endometrial Cancer

Immunotherapy After Immunotherapy, What Are The Opportunities for Immune Check-Point Inhibition Re-challenge and The Role of Pembrolizumab/Lenvatinib

 IGCS and Eisai welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the first presentation from the An Evolving Frontier - Understanding Novel Treatment Options for The Management of Advanced Stage or Recurrent Endometrial Cancers Industry Supported Symposium presented at the IGCS 2023 Annual Global Meeting in Seoul, Korea. 

 Stephanie Lheureux, MD, PhD
Princess Margaret Cancer Centre

STEPHANIE LHEUREUX MD, PhD is a Medical Oncologist, Clinician Investigator, Site Lead of Gynecology Oncology and co-director of the Beyond Chemotherapy Program at Princess Margaret Cancer Centre. She holds the Westaway Chair in Ovarian Cancer Research and is an Associate Professor of Faculty of Medicine at the University of Toronto. Her clinical and academic interests are focused in gynecologic cancers and early drug development with an emphasis on translational research and have garnered two ASCO Merit awards. She received the 2019 Career Development Award from the American Society of Clinical Oncology (ASCO) and the 2021 Young Investigator Award from University of Toronto Division of Medical Oncology. Internationally, she is co-Chair of the Translational Research Committee and Director representing Princess Margaret Consortium at the international Gynecologic Cancer InterGroup (GCIG). She is also a member of the Gynecologic Cancer Steering Committees at the US National Cancer Institute. In the last five years, she has >60 peer-reviewed publications in widely cited journals such as CA: Cancer Journal for Clinicians, Clinical Cancer Research, JAMA Oncology, Journal of Clinical Oncology, Lancet, Lancet Oncology and Gynecology Oncology. She is principal investigator or co-principal investigator of different clinical trials and in several large-scale peer reviewed funding opportunities from the Canadian Cancer Society Research Institute, Conquer Cancer Foundation/American Society for Clinical Oncology, Ontario Institute for Cancer Research, Ovarian Cancer Canada and Terry Fox Research Institute that converge preclinical and clinical areas of interest. 

Eisai have sponsored this initiative with IGCS and had no input into or influence over the content.

Leave a Reply